Bismethylene triphosphate nucleotides of uridine 4-phosphate analogues: A new class of anionic pyrimidine nucleotide analogues

Journal of Organic Chemistry

Volumn 73, Issue 4, 2008, Pages 1403-1412

  Taylor, Scott D ^a   Mirzaei, Farzad ^a   Bearne, Stephen L ^b  

^a UNIVERSITY OF WATERLOO   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER AGENTS; ANTIVIRAL AGENTS; ESTER MOIETY; METHANOLYSIS;

NUCLEOTIDES; REACTION KINETICS;

AROMATIC COMPOUNDS;

(BROMOMETHYLBENZYLOXYPHOPHINOYLMETHYL)PHOSPHONIC ACID DIBENZYLESTER; 2',3' DI O ACETYL 5' [BIS[(BENZYLOXYPHOSPHORYLMETHYL)BENZYLOXYPHORYLMETHYL]METHYLOXYPHOSPORYL] CYTIDINE 4 N [O,O BIS(2 CYANOETHYL)PHOSPHORAMIDATE]; 2',3' DI O ACETYLCYTIDINE 4 N [O,O BIS(2 CYANETHYL)PHOPHORAMIDATE]; 2',3',5' TRI O ACETYLCYTIDINE 4 N [O,O BIS(2 CYANETHYL)PHOPHORAMIDATE]; 5' [BIS[(DIHYDROXYPHOSPHORYLMETHYL)HYDROXYPHORYLMETHYL]HYDROXYPHOSPORYL]CYTIDINE 4 N PHOSPHORAMIDIC ACID; [(DIBENZYLOXYPHOSPHORYLMETHYL)BENZYLOXYPHOSPHINOYLMETHYL]PHOSPHONIC ACID DIMETHYLESTER; [1 [3,4 BIS(BENZOYLOXY) 5 [BIS[(BENZYLOXYPHOSPHORYLMETHYL)BENZYLOXYPHOSPHORYLMETHYL]METHYLOXY PHOSPHORYL]TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4 YLMETHYL]PHOSPHONIC ACID DIMETHYLESTER; [1 [3,4 BIS(BENZOYLOXY) 5 [BIS[(BENZYLOXYPHOSPHORYLMETHYL)BENZYLOXYPHOSPHORYLMETHYL]METHYLOXY PHOSPHORYL]TETRAHYDROFURAN 2 YL] 2 OXO 2,3 DIHYDROPYRIDIN 1H PYRIMIDIN 4 YLIDENEMETHYL]PHOSPHONIC ACID DIMETHYLESTER; [1 [3,4 BIS(BENZOYLOXY) 5 HYDROXYMETHYLTETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4 YLMETHYL]PHOSPHONIC ACID DIMETHYLESTER; [1 [3,4 BIS(BENZOYLOXY) 5 HYDROXYMETHYLTETRAHYDROFURAN 2 YL] 2 OXO 2,3 DIHYDROPYRIDIN 1H PYRIMIDIN 4 YLIDINEMETHYL]PHOSPHONIC ACID DIMETHYLESTER; [1 [3,4 BIS(HYDROXY) 5 [[(DIHYDROXYPHOSPHORYLMETHYL)HYDROXYPHOSPHORYLMETHYL]HYDROPHOSPHORYL] TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4 YLMETHYL]PHOSPHONIC ACID; [1 [3,4 BIS(HYDROXY) 5 [[(DIHYDROXYPHOSPHORYLMETHYL)HYDROXYPHOSPHORYLMETHYL]HYDROPHOSPHORYL] TETRAHYDROFURAN 2 YL] 2 OXO 2,3 DIHYDRO 1H PYRIMIDIN 4 YLIDENEMETHYL]PHOSPHONIC ACID; [DIFLUORO [1 [3,4 BIS(ACETOXY) 5 [BIS[(BENZYLOXYPHOSPHORYLMETHYL)BENZYLOXYPHOSPHORYLMETHYL]METHOXY PHOSPHORYL]TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4 YL]METHYL]PHOSPHONIC ACID DIETHYLESTER; [DIFLUORO [1 [3,4 BIS(ACETOXY) 5 HYDROXYMETHYLTETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4YL]METHYL]PHOSPHONIC ACID DIETHYLESTER; [DIFLUORO [1 [3,4 BIS(HYDROXY) 5 [BIS[(DIHYDROXYPHOSPHORYLMETHYL)HYDROXYLPHOSPHORYLMETHYL]HYDROXYPHOSPHORYL] TETRAHYDROFURAN 2 YL] 2 OXO 1,2 DIHYDROPYRIDIN 4 YL]METHYL]PHOSPHONIC ACID; ESTER DERIVATIVE; FUNCTIONAL GROUP; NUCLEOTIDE; PHOSPHONIC ACID DERIVATIVE; PHOSPHORAMIDIC ACID DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; TIN; UNCLASSIFIED DRUG; URIDINE PHOSPHATE;

ARTICLE; CATALYST; DEPROTECTION REACTION; DRUG PURIFICATION; DRUG SYNTHESIS; METHANOLYSIS; MITSUNOBU REACTION;

MAGNETIC RESONANCE SPECTROSCOPY; NUCLEIC ACID CONFORMATION; PYRIMIDINE NUCLEOTIDES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 39349092031     PISSN: 00223263     EISSN: None     Source Type: Journal    
DOI: 10.1021/jo702249j     Document Type: Article

References (77)

1. (a) Jordheim, L. P.; Galmarini, C. M.; Dumontet,C. Recent Patents on Anti-Cancer Drug Discovery 2006, 1, 163.
2. (b) Carroll, S. S.; Olen, D. B. Infectious Disorders: Drug Targets 2006, 6, 17.
3. (a) Long, C. W.; Levitzki, A.; Koshland, D. E., Jr. J. Biol. Chem. 1979, 245, 80.
4. (b) Koshland, D. E., Jr.; Levitzki, A. Biochemistry 1971, 10, 3365.
5. (c) Long, C. W.; Pardee, A. B. J. Biol. Chem. 1967, 242, 4715.
6. (d) von der Saal, W.; Villafranca, J. J.; Anderson, P. M. J. Am. Chem. Soc. 1985, 107, 703.
7. (e) von der Saal, W.; Anderson, P. M.; Villafranca, J. J. J. Biol. Chem. 1985, 260, 14993.
8. (f) Levitzki, A.; Koshland, D. E., Jr. Biochemistry 1972, 11, 241.
9. (g) Levitzki, A.; Koshland, D. E., Jr. Biochemistry 1971, 10, 3365.
10. (h) Lewis, D. A.; Villafranca, J. J. Biochemistry 1989, 28, 8454.
11. (a) Ellims, P. H.; Gan, T. E.; Medley, G. Cancer Res. 1983, 43, 1432.
12. (b) Verschuur, A. C.; van Gennip, A. H.; Muller, E. U. J.; Voute, P. A.; van Kuilenburg, A. B. Adv. Exp. Med. Biol. 1998, 431, 667.
13. Kizaki, H.; Williams, J. C.; Morris, H. P.; Weber, G. Cancer Res. 1980, 40, 3921.
14. Kennedy, E. P. In Lipids and membranes: Past, present and future; Op den Kamp, J. A. F., Roelofsen, B., Wirtz, K. W. A., Eds.; Elsevier Scientific Publishers: Amsterdam, The Netherlands, 1986; pp 171-206
15. Hatse, S.; De Clercq; E.; Balzarini, J. Biochem. Pharmacol. 1999, 15, 58, 539.
16. Kensler, T. W.; Cooney, D. A. In Design of Enzyme Inhibitors as Drugs; Sandler, M., Smith, H. J., Eds.; Oxford University Press: New York, 1989; pp 379-401.
17. Savickiene, J.; Gineitis, A. Int. J. Biochem. Cell Biol. 2003, 35, 1482.
18. (a) Barlogie, B.; Plunkett, W.; Raber, M.; Latreille, J.; Keating, J.; McCredie, K. B. Cancer Res. 1981, 41, 1227.
19. (b) Mills-Yamamoto, C.; Lauzon, G. J.; Peterson, A. R. P. Biochem. Pharmacol. 1978, 27, 181.
20. (c) Momparler, R, L.; Momparler, L. F. Cancer Chemother. Pharmacol. 1989, 25, 51.
21. (d) Momparler, R. L; Bouffard, D. Y.; Momparler, L. F.; Marquet, J.; Zittoun, J.; Marie, J-P.; Zittoun, R. Int. J. Cancer 1991, 49, 573.
22. (e) Momparler, R. L.; Vesely, J.; Momparler, L. F.; Rivard, G. E. Cancer Res. 1979, 39, 573.
23. (f) Bouffard, D. Y.; Momparler, L. F.; Momparler, R. L. Anticancer Drugs 1994, 5, 223.
24. Kang, G. J.; Cooney, D. A.; Moyer, J. D.; Kelley, J. A.; Kim, H-Y.; Marquez, V. E.; Johns, D. G. J. Biol. Chem. 1989, 264, 713.
25. McPartland, R. P.; Wang, M. C.; Bloch, A.; Weinfeld, H. Cancer Res. 1974, 34, 3107.
26. (a) De Clercq, E.; Murase, J.; Marquez, V. E. Biochem. Pharmacol. 1991, 41, 1821.
27. (b) Gao, W. Y.; Johns, D. G.; Mitsuya Nucleosides Nucleotides Nucleic Acids 2000, 19, 371.
28. (a) Hendriks, E. F.; O'Sullivan, W. J.; Stewart, T. S. Biochim. Biophys. Acta 1998, 1399, 213.
29. (b) Hofer, A.; Steverding, D.; Chabes, A.; Brun, R.; Thelander, L. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 6412.
30. (c) Fijolek, A.; Hofer, A.; Thelander, L. J. Biol. Chem. 2007, 282, 11858.
31. (a) Wolfenden, R. Acc. Chem. Res. 1972, 5, 10.
32. (b) Wolfenden, R. Ann. Rev. Biophys. Bioeng. 1976, 5, 271.
33. Taylor, S. D.; Mirzaei, F.; Bearne, S. L. J. Org. Chem. 2006, 71, 9420.
34. (a) Maguire, M. H.; Ralph, R. K.; Shaw, G. J. Chem. Soc. 1958, 2299.
35. (b) Inoue, H.; Tomita, S.; Ueda, T. Chem. Pharm. Bull. 1975, 23, 2614.
36. (c) Honjo, M.; Maruyama, T.; Horikawa, M.; Baizarini, J.; De Clercq, E. Chem. Pharm. Bull. 1987, 35, 3227.
37. Wada, T.; Moriguchi, T.; Sekine, M. J. Am. Chem. Soc. 1994, 116, 9901.
38. Moriguchi, T.; Wada, T.; Sekine, M. Eur. J. Org. Chem. 2003, 2260.
39. For some examples: (a) Biller, S.; Forster, C. Tetrahedron, 1990, 46, 6645.
40. (b) Blackburn, G. M.; Langston, S. P. Tetrahedron Lett. 1991, 32, 6425.
41. (c) Morr, M.; Wray, V. Angew. Chem., Int. Ed. Engl. 1994, 33, 1394.
42. (d) Yanachkov, I.; Pan, J. Y.; Wessling-Resnick, M.; Wright, G. E. Mol. Pharmacol. 1997, 51, 47.
43. (e) Ma, Q-F.; Kenyon, G. L.; Markham, G. D. Biochemistry 1990, 29, 1412.
44. (f) Dalton, A.; Hornby, D. P.; Langston, S. P.; Blackburn, G. M. Biochem. J. 1992, 287, 871.
45. (g) Labataille, P.; Pelicano, H.; Maury, G.; Imbach, J.-L.; Gosselin, G. Biooorg. Med. Chem. Lett. 1995, 5, 2315.
46. (h) Spelta, V.; Mekhalfia, A.; Rejman, D.; Thompson, M.; Blackburn, G. M.; North, R. A. Br. J. Pharmacol. 2003, 140, 1027.
47. (i) Towbridge, D. B.; Yamamoto, D. M.; Kenyon, G. L. J. Am. Chem. Soc. 1972, 94, 3816.
48. (j) Stock, J. A. J. Org. Chem. 1979, 44, 3997.
49. (k) Blackburn, G. M.; Guo, M. J.; Langston, S. P.; Taylor, G. E. Tetrahedron Lett. 1990, 31, 5637.
50. (a) Klein, E.; Mons, S.; Valleix, A.; Mioskowski, M.; Lebeau, L. J. Org. Chem. 2002, 67, 146.
51. (b) Brossette, T.; Le Faou, A.; Goujon, L.; Valleix, A.; Creminon, C.; Grassi, J.; Mioskowski, C.; Lebeau, L. J. Org. Chem. 1999, 64, 5083.
52. (c) Klein, E.; Nghiem, H.-O.; Valliex, A.; Mioskowski, C.; Lebeau, L. Chem. Eur. J. 2002, 8, 4649.
53. Taylor, S. D.; Mirzaei, F.; Bearne, S. L. Org. Lett. 2006, 8, 4243.
54. Cook, P. D.; Day, R. T.; Robins, R. K. J. Heterocycl. Chem. 1997, 14, 1295.
55. (a) Singh, H. K.; Cote, G. L.; Sikorski, R. S. Tetrahedron Lett. 1993, 34, 5201.
56. (b) Kuboki, A.; Ishihara, T.; Kobayashi, E.; Ohta, H.; Ishii, T.; Inoue, A.; Mitsuda, S.; Miyazaki, T.; Kajhara, Y.; Sugai, T. Biosci. Biotechnol. Biochem. 2000, 64, 363.
57. Ren, B.; Cai, L.; Zhang, L-R.; Yang, Z-J.; Zhang, L-H. Tetrahedron Lett. 2005, 46, 8083.
58. Orita, A.; Hamada, Y.; Nakano, T.; Toyoshima, S.; Otera, J. J. Chem. Eur. J. 2001, 7, 3321.
59. Matulic-Adamic, J.; Gonzalez, C.; Usman, N.; Beigelman, L. Bioorg. Med. Chem. Lett. 1996, 373.
60. Chavis, C.; Dumont, F.; Wightman, H.; Zeigler, H. C.; Imbach, J. L. J. Org. Chem. 1982, 47, 202.
61. 31P NMR suggested that one of these compounds was compound 39 but we could not obtain it in pure form.
62. Saady, M.; Lebeau, L.; Mioskowski, C. Helv. Chim. Acta 1995, 78, 670.
63. 1H NMR of compound 28. These include the following: (a) the doublet corresponding to phosphoramidate N-H proton in 28 is no longer evident,
64. (b) downfield shifts with increased geminal coupling for the two diastereotopic protons attached to C-5′,
65. (c) an upfield shift of about 0.4 ppm for the H-1′ proton, and
66. (d) a downfield shift of approximately 0.5 ppm for the H-5 proton. Similar differences were also found between compound 27 and the product that was isolated from the attempted Mitsunobu reaction of phosphoramidate 27 and 44. All of these changes are consistent with the conversion of a nucleoside into a 1,5-anhydro nucleoside (see refs 32a-c).
67. Napierzaj, A.; Zaeadzki, S.; Zwierzak, A. Tetrahedron 2000, 56, 6299.
68. (a) Shibuya, S.; Kuninaka, A.; Hiroshi, Y. Chem. Pharm. Bull. 1974, 22, 719.
69. (b) Kimura, J.; Fujisawa, Y.; Sawada, T. Chem. Lett. 1974, 691.
70. (c) Li., H.; Miller, M. J. J. Org. Chem. 1999, 64, 9289.
71. Saady, M.; Lebeau, L.; Mioskowski, C. Tetrahedron Lett. 1995, 36, 2239.
72. We have also attempted to convert phosphonic acid 44 to the corresponding phosphonyl chloride in situ and then react the crude phosphonyl chloride with 28. However, only trace amounts of the coupled product were obtained using this procedure.
73. 2O at room temperature. The dephosphorylation is presumed to proceed by a metaphosphate intermediate.
74. Nowak, I.; Conda-Sheridan, M.; Robins, M. J. J. Org. Chem. 2005, 70, 7455.
75. Gaffney, P. R.; Reese, C. B. J. Chem. Soc. Perkin 2001, 1, 192.
76. (a) Chu, C. V.; Murray, J. D. J. Chem. Soc. A 1971, 360.
77. (b) Puff, H.; Hevendehl, H.; Hoffer, K.; Reuter, H.; Schuh, W. Organomet. Chem. 1985, 287, 163.